Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 19,493	$ 6,602
Restricted cash		4
Prepaid expenses and other current assets	163	177
Total current assets	19,656	6,783
Property, equipment and leasehold improvements, net	85	73
Restricted cash - non current	110	110
Operating lease right-of-use assets	928	1,211
Prepaid clinical trial expenses	1,122	1,122
Other assets	9	26
Total assets	21,910	9,325
Current liabilities:
Accounts payable	481	942
Operating lease liabilities	327	294
Accrued expenses	1,164	1,427
Total current liabilities	1,972	2,663
Other liabilities	59	59
Operating lease liabilities - non current	693	1,020
Total liabilities	2,724	3,742
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock, $0.00001 par value, authorized 50,000,000 shares; 23,631,886 shares issued and outstanding, including 6,302 shares of unvested restricted stock, at December 31, 2020; authorized 16,666,667 shares; 550,736 shares issued and outstanding, including 6,886 shares of unvested restricted stock, at December 31, 2019	3	2
Additional paid-in capital	247,417	224,741
Accumulated deficit	(228,234)	(219,160)
Total stockholders’ equity	19,186	5,583
Total liabilities and stockholders’ equity	$ 21,910	$ 9,325